ArticleEye (London, England)2024
Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy.
Article in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures.Pediatric rheumatology online journal · 2026Article
- Novel advances in juvenile idiopathic arthritis associated uveitis.Arthritis research & therapy · 2026Review
- The effect of anti-TNF α therapy on refractory non-infectious pediatric uveitis in Saudi Arabia.BMC ophthalmology · 2026Article
- Advances in tumor necrosis factor-α inhibitors for the treatment of juvenile idiopathic arthritis-associated uveitis.Frontiers in immunology · 2026Review
- Immunogenicity of adalimumab in patients with noninfectious uveitis based on therapeutic drug monitoring.Journal of translational medicine · 2025Article
- Treatment outcomes of a Swiss non-infectious paediatric uveitis cohort: retrospective study over ten years.Journal of ophthalmic inflammation and infection · 2025Article
- Immune responses in retinal gene therapy: challenges, mechanisms, and future strategies.Frontiers in immunology · 2025Review
- The management of adult and paediatric uveitis for rheumatologists.Nature reviews. Rheumatology · 2024Review
- Use of immunomodulators in non-infectious uveitis: lights and shadows.Eye (London, England) · 2024Review
- To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the I anti-TNF.Journal of translational autoimmunity · 2024Review
- Paediatric Uveitis - the uniqueness in clinical presentation and the efficacy of biologics treatment.Journal of ophthalmic inflammation and infection · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
Abstract
objectivesTo examine the outcome of infliximab treatment in patients with non-infectious paediatric uveitis who have previously failed biologic treatment.
methodsA retrospective cohort study was performed at Bristol Eye Hospital, UK. Paediatric patients with chronic non-infectious uveitis who had been switched to infliximab due to inadequate uveitis control were identified. Two separate groups were evaluated: group 1 consisted of 20 children (36 eyes) who had been switched to infliximab following treatment failure with adalimumab (=in-class switching), while group 2 (5 patients; 9 eyes) included those who had been switched to infliximab from a non-TNF antagonist after failing several biologics (=across-class switching). The change in anterior chamber (AC) activity between baseline and 6- and 24-months follow-up was the primary outcome measure.
resultsA statistically significant reduction in AC activity was found between baseline and 6-months follow-up (RE: p = 0.002; LE: p < 0.001) and between baseline and 24-months follow-up (RE: p = 0.016; LE: p = 0.011) in group 1. No statistically significant difference was found for either eye in the number of steroid eye drops needed between time points or the difference in visual acuity in time. In group 2, analysis of change of AC activity, number of steroid eye drops and visual acuity failed to reach statistical significance. Treatment failure occurred in four patients (20% of group 1) and adverse events developed in six patients including three patients with acute infusion reactions.
conclusionsThis study supports the efficacy and safety of infliximab in adalimumab-refractory patients with paediatric non-infectious uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.